Literature DB >> 3700480

Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. II. Evidence for a pentasaccharide sequence that contains a 3-O-sulfate group.

J J Castellot, J Choay, J C Lormeau, M Petitou, E Sache, M J Karnovsky.   

Abstract

Earlier work from our laboratory demonstrated that heparin inhibited the proliferation of vascular smooth muscle cells in vivo and in vitro. Both anticoagulant and non-anticoagulant heparin species were equally effective as antiproliferative agents. Previous structure-function studies indicated that hexasaccharide and larger fragments retained antiproliferative activity, whereas tetra- and disaccharides were inactive. These experiments also suggested that both N- and O-sulfates of heparin were necessary for growth inhibitory capacity. In this paper, we have further analyzed the structural determinants of the antiproliferative activity of heparin. These experiments were done using synthetically prepared and therefore chemically defined heparin oligosaccharides. We present evidence that a pentasaccharide fragment retains antiproliferative activity, and that the 3-O-sulfate on the internal glucosamine residue is critical for growth inhibitory capacity of the pentasaccharide. We also show that heparins obtained from different manufacturers differ significantly in their ability to suppress smooth muscle cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3700480      PMCID: PMC2114207          DOI: 10.1083/jcb.102.5.1979

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  19 in total

1.  Inhibition of purified plasma kallikrein by antithrombin III and heparin.

Authors:  A M Venneröd; K Laake
Journal:  Thromb Res       Date:  1975-07       Impact factor: 3.944

2.  The inhibition of human plasma kallikrein by antithrombin III.

Authors:  C E Burrowes; F M Habal; H Z Movat
Journal:  Thromb Res       Date:  1975-07       Impact factor: 3.944

3.  Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238).

Authors:  M L Larsen; U Abildgaard; A N Teien; K Gjesdal
Journal:  Thromb Res       Date:  1978-08       Impact factor: 3.944

4.  Suppression by heparin of smooth muscle cell proliferation in injured arteries.

Authors:  A W Clowes; M J Karnowsky
Journal:  Nature       Date:  1977-02-17       Impact factor: 49.962

5.  Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin.

Authors:  J R Guyton; R D Rosenberg; A W Clowes; M J Karnovsky
Journal:  Circ Res       Date:  1980-05       Impact factor: 17.367

6.  Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis.

Authors:  R Ross; J A Glomset
Journal:  Science       Date:  1973-06-29       Impact factor: 47.728

7.  Inhibition of rat arterial smooth muscle cell proliferation by heparin. II. In vitro studies.

Authors:  R L Hoover; R Rosenberg; W Haering; M J Karnovsky
Journal:  Circ Res       Date:  1980-10       Impact factor: 17.367

8.  Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase.

Authors:  M D Kazatchkine; D T Fearon; D D Metcalfe; R D Rosenberg; K F Austen
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

9.  The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers.

Authors:  R Ross
Journal:  J Cell Biol       Date:  1971-07       Impact factor: 10.539

10.  Myosin in cultured vascular smooth muscle cells: immunofluorescence and immunochemical studies of alterations in antigenic expression.

Authors:  D M Larson; K Fujiwara; R W Alexander; M A Gimbrone
Journal:  J Cell Biol       Date:  1984-11       Impact factor: 10.539

View more
  29 in total

Review 1.  Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering.

Authors:  Jeffrey A Beamish; Ping He; Kandice Kottke-Marchant; Roger E Marchant
Journal:  Tissue Eng Part B Rev       Date:  2010-10       Impact factor: 6.389

2.  Derivation and properties of platelet-derived growth factor-independent rat smooth muscle cells.

Authors:  S M Schwartz; L Foy; D F Bowen-Pope; R Ross
Journal:  Am J Pathol       Date:  1990-06       Impact factor: 4.307

3.  Voltage-activated potassium, but not calcium currents in cultured bovine aortic endothelial cells.

Authors:  K Takeda; V Schini; H Stoeckel
Journal:  Pflugers Arch       Date:  1987-11       Impact factor: 3.657

Review 4.  Angiostatic steroids. Method of discovery and mechanism of action.

Authors:  J Folkman; D E Ingber
Journal:  Ann Surg       Date:  1987-09       Impact factor: 12.969

5.  Endothelial stimulation of intimal cell proliferation in a porcine aortic organ culture.

Authors:  E W Koo; A I Gotlieb
Journal:  Am J Pathol       Date:  1989-03       Impact factor: 4.307

6.  Immunohistochemical study of fibronectin in experimental myocardial infarction.

Authors:  W Casscells; H Kimura; J A Sanchez; Z X Yu; V J Ferrans
Journal:  Am J Pathol       Date:  1990-10       Impact factor: 4.307

7.  In vitro stimulation of human endothelial cells by derivatized dextrans.

Authors:  D Letourneur; J Champion; F Slaoui; J Jozefonvicz
Journal:  In Vitro Cell Dev Biol       Date:  1993-01

8.  Heparin and hormonal regulation of mRNA synthesis and abundance of autocrine growth factors: relevance to clonal growth of tumors.

Authors:  I Zvibel; E Halay; L M Reid
Journal:  Mol Cell Biol       Date:  1991-01       Impact factor: 4.272

9.  Differential binding of platelet-derived growth factor isoforms to glycosaminoglycans.

Authors:  Raquel García-Olivas; Johan Hoebeke; Susanna Castel; Manuel Reina; Gunnar Fager; Florentina Lustig; Senén Vilaró
Journal:  Histochem Cell Biol       Date:  2003-10-14       Impact factor: 4.304

10.  The effects of heparin releasing hydrogels on vascular smooth muscle cell phenotype.

Authors:  Jeffrey A Beamish; Leah C Geyer; Nada A Haq-Siddiqi; Kandice Kottke-Marchant; Roger E Marchant
Journal:  Biomaterials       Date:  2009-08-26       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.